Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.

Cancer chemotherapy and pharmacology - 1 Aug 2016

Teuma Cécile, Perier-Muzet Marie, Pelletier Solenne, Nouvier Mathilde, Amini-Adl Mona, Dijoud Frédérique, Duru Gérard, Thomas Luc, Fouque Denis, Laville Maurice, Dalle Stéphane

Abstract excerpt

PURPOSE: Vemurafenib (VMF) is a B-RAF inhibitor used in the treatment of B-RAF-V600-mutant metastatic melanomas. Reports of acute kidney injury (AKI) in patients treated with VMF are scarce. METHODS: To investigate the incidence and severity of AKI, we conducted a retrospective, observational, monocentric study in the Lyon Sud Hospital University, France, which included 74 patients with metastatic B-RAF-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Kidney Injury
Share to Creatinine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to Indoles

Share to Melanoma

Share to Neoplasm Metastasis

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 27371224
DOI: 10.1007/s00280-016-3086-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.PMID 27371224Read ↗

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.Semantic proximity Read ↗

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.Semantic proximity Read ↗

Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib is driven by off-target Ferrochelatase inhibitionSemantic proximity Read ↗

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.Semantic proximity Read ↗

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.Semantic proximity Read ↗

Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).Semantic proximity Read ↗

Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report.Semantic proximity Read ↗

[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].Semantic proximity Read ↗

Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport.Semantic proximity Read ↗

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.